Articles from NeoGenomics, Inc.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.

NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQNEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.

NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQNEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Chris Smith, Chief Executive Officer, will deliver a presentation followed by Q&A on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City.

NeoGenomics, Inc. (NASDAQNEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that the New York State Department of Health (NYSDOH) has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE® DNA & RNA Lung, allowing for immediate commercial access in the state of New York. These next-generation sequencing (NGS) tests deliver better diagnostic value and cost-effectiveness than single gene testing and direct the first-line treatment of diverse solid tumors, including non-small cell lung cancer.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today issued the following statement in response to inquiries:

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438). NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their role in early diagnosis and treatment optimization.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will attend the Morgan Stanley 22nd Annual Global Healthcare Conference. Chris Smith, Chief Executive Officer, Jeff Sherman, Chief Financial Officer, and Warren Stone, Chief Commercial Officer, will participate in an in-person fireside chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York City.

NeoGenomics, Inc. (NASDAQNEO) (the “Company”), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in Fort Myers, NeoGenomics serves over 600,000 patients each year and is on a mission to serve one million patients annually by 2028.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).

NeoGenomics, Inc. (NASDAQNEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company management will host a webcast and conference call that morning at 8:30 a.m. Eastern Time to discuss financial results and recent highlights.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5-10 (booth #915), demonstrating its commitment to advancing cancer patient care through innovative research and development initiatives.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today released its 2023 Environmental, Social, and Governance (ESG) Report highlighting progress toward building a more sustainable, diverse, and equitable company that delivers exceptional customer experience and advanced testing options. This inaugural report details the performance and management of NeoGenomics’ commitment to its core values of quality, integrity, accountability, teamwork, and innovation.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced the company will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts.

NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that the Company has signed the Working with Cancer Pledge. By taking the pledge, NeoGenomics demonstrates its commitment to supporting team members living with or caring for a loved one with cancer. Additionally, the company aims to open the conversation around cancer in the workplace and ensure our employees are aware of the resources available to them.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board

FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its second quarter 2022, financial results on Tuesday, August 9, 2022.

FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced new data in support of its RaDaRTM assay for the detection of minimal residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in multiple upcoming institutional investor conferences.

CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D

FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQNEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq., the current Executive Chair and Principal Executive Officer, as Chair of the Board and Interim CEO as of May 12, 2022. Ms. Tetrault has been serving as Executive Chair since March when the

FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") together with collaborators will present new data on its RaDaR® assay for the detection of minimal residual disease (MRD) and recurrence at the American Society of Clinical

FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Dr. Clive Morris. Vishal will officially join NeoGenomics on May 23, 2022 and Dr. Morris will assist in the leadership

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

First-Quarter 2022 Results - Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% - Clinical Services revenue increased 2% to $99 million; excluding 2021 COVID-19 PCR testing revenue, Clinical Services revenue increased 4% - Pharma Services revenue decreased 4% to $18 million FORT MYERS, FL / ACCESSWIRE / April 27, 2022 / NeoGenomics, Inc. (NASDAQNEO) (the " Company

FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost. The Lilly Lung Cancer Sponsored Testing Program will utilize the NeoTYPE®

Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancer FT. MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has unveiled new data at the American Association for Cancer Research (AACR)

NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companies FORT MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of oncology testing and global contract research services announced a global strategic partnership agreement with Biognosys AG, a Switzerland-based leader in next-generation proteomics

FT. MYERS, FL / ACCESSWIRE / April 8, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2022, financial results on Wednesday, April 27, 2022. The Company has scheduled a webcast and conference call to discuss their first quarter 2022 results on Wednesday, April 27, 2022 at 8:30 AM EDT. Interested investors

Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance FT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc. (NASDAQNEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that the Board of Directors (the "Board") and Mark Mallon, Chief Executive Officer, have

Study further highlights potential of RaDaR to stratify patients and improve treatment outcomes FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced the publication of new data in support of its RaDaR™ liquid

FT MYERS, FL / ACCESSWIRE / March 2, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in multiple upcoming institutional investor conferences. - Management will participate in investor meetings and a fireside chat at the Raymond James 43rd Annual Institutional Investors Conference in

Recent Highlights: - Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16% - Fourth quarter consolidated revenue was flat year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 7% - Inivata Limited, a wholly owned subsidiary of NeoGenomics ("Inivata"), received the CE mark for its RaDaR™ assay in January 2022 for the

FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced that Shashikant Kulkarni, M.S (Medicine)., Ph.D., MBA, FACMG will be joining the NeoGenomics executive team as Executive Vice President for Research & Development and Chief Scientific Officer on March 7th. Dr. Kulkarni most recently served

RaDaR demonstrated 100% specificity in patients with no recurrence and 100% sensitivity in patients with clinical recurrence FT MYERS, FL / ACCESSWIRE / February 11, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced clinical validation data for its

FT. MYERS, FL / ACCESSWIRE / February 8, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that members of senior management will be participating virtually in multiple upcoming institutional investor conferences. - Management will participate in investor meetings and a fireside chat at the SVB Leerink Virtual 11th Annual Global

FT MYERS, FL / ACCESSWIRE / February 2, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its fourth quarter 2021, financial results on Wednesday, February 23, 2022. The Company has scheduled a webcast and conference call to discuss their fourth quarter and full year 2021 results on Wednesday, February 23, 2022 at 8:30 AM

The partnership makes it possible for patients with specific biomarkers to get early support FT. MYERS, FL / ACCESSWIRE / January 24, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced a strategic partnership with the Biomarker Collaborative to help cancer patients who test positive for specific biomarkers connect to support groups that

FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has received the CE mark for its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro

FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the appointment of David Eberhard MD, PhD as Chief Medical Officer (CMO) of its liquid biopsy focused subsidiary Inivata Limited ("Inivata"). David will report to Inivata President Clive Morris and will oversee the clinical and strategic

FT. MYERS, FL / ACCESSWIRE / December 10, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced it will use Thermo Fisher Scientific's Ion Torrent Genexus System, the first turnkey next-generation sequencing (NGS) solution that automates the specimen-to-report workflow to deliver results in as little as a single day, in a pharma-sponsored

FT. MYERS, FL / ACCESSWIRE / November 30, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Bill Bonello, President - Informatics Division, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Stephens Annual Investment Conference 2021 held in Nashville,

FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has appointed Dave Daly to serve on its Board of Directors. Dave Daly joined our Board of Directors effective November 10, 2021. Mr. Daly currently serves as the President and Chief Operating Officer at Singular Genomics, a novel next generation sequencing

Third-Quarter 2021 Results and Highlights: - Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million - Consolidated revenue decreased 3% due to the discontinuation of prior year COVID-19 revenue; consolidated revenue increased 12% when excluding prior year COVID-19 revenue - Announces plan to double its Clinical Services sales and medical affairs teams to further

FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today an upcoming leadership team transition. William Bonello will be named Chief Financial Officer as of January 1, 2022. Mr. Bonello currently serves as President of our Informatics Division. He has led the division since its inception in 2020,

Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has entered into a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for

FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its third quarter 2021, financial results on Thursday, November 4, 2021. The Company has scheduled a webcast and conference call to discuss their third quarter results on Thursday, November 4, 2021 at 8:30 AM EDT. Interested investors

Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT. MYERS, FL / ACCESSWIRE / October 12, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today a transition in the leadership of its Board of

FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") alongside collaborators, will present new data on its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence and on its

FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Morgan Stanley 19th Annual Global Healthcare Conference, on

Second-Quarter 2021 Results and Highlights: - Consolidated revenue increased 40% to $122 million - Clinical Services revenue increased 37% to $101 million - Pharma Services revenue increased 55% to $20 million - Completed the acquisitions of Trapelo Health in April and Inivata Limited in June FORT MYERS, FL / ACCESSWIRE / August 6, 2021 / NeoGenomics, Inc. (NASDAQNEO) (the "Company"), a leading provider of cancer-focused genetics testing

FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its second quarter 2021, financial results on Friday, August 6, 2021. The Company has scheduled a webcast and conference call to discuss their first quarter results on Friday, August 6, 2021 at 8:30 AM EDT. Interested investors should dial

- Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has completed its acquisition of Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in

FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating virtually in multiple upcoming institutional investor conferences. - Management will participate in investor meetings at the 18th Annual Craig-Hallum Institutional Investor Conference on

FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathryn McKenzie, Chief Financial Officer, will be presenting at the Bank of America 2021 Health Care Conference, on Wednesday, May 12, 2021 at 4:15pm

First-Quarter 2021 Results and Highlights: - Consolidated revenue increased 9% to $116 million - Clinical Services revenue increased 4% to $96 million - Pharma Services revenue increased 46% to $19 million - Completed the acquisition of Trapelo Health in April FORT MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQNEO) (the "Company"), a leading provider of cancer-focused genetics testing

Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million Completes $200 million strategic financing with leading oncology-focused specialist investors FT. MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services

SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, is excited to launch an Amgen-sponsored testing program to support single-gene molecular testing for the biomarker KRAS G12C for eligible lung cancer

FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the 20th Annual Needham Virtual Healthcare Conference 2021, on Thursday, April 15, 2021 at 11:00am

FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQNEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2021, financial results on Wednesday, May 5, 2021. The Company has scheduled a webcast and conference call to discuss their first quarter results on Wednesday, May 5, 2021 at 8:30 AM EDT. Interested investors should